Active ingredient Abciximab interacts in the following cases:
It is also not known whether abciximab can cause foetal harm when administered to a pregnant woman. ReoPro should not be used during pregnancy unless clearly necessary.
Breast-feeding of infants should be discontinued in breast-feeding mothers, since the secretion of abciximab in animal or human breast milk has not been studied.
Carcinogenesis, Mutagenesis and Fertility
Animal reproduction studies have not been conducted with abciximab. It is also not known whether abciximab can affect reproduction capacity.
Effects on Ability to Drive and Use Machines